Pharvaris N.V. (NasdaqGS: PHVS)
Health Care · Pharmaceuticals · CH
$36.89
+1.71% today · +53.4% 1Y
Pharvaris N.V. (NasdaqGS: PHVS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.55B and employs 134 people.
Over the last twelve months the share price has gained 53.4%, trading between 20.65 and 36.93.
Tweenvest scores Pharvaris N.V. across four factors: quality 27/100. Its strongest factor is quality.
PHVS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.55B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.62
- Dividend yield
- —
- Beta (5Y)
- -2.33
- 52-week high
- $36.93
- 52-week low
- $20.65
- Avg volume (3M)
- —
- Shares outstanding
- 70.20M
- Employees
- 134
- Next earnings
- —
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- ISIN
- NL00150005Y4
- Founded
- 2015
- Listed since
- Feb 4, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,253.00 | +0.49% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.09 | +0.02% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $154.72 | +2.69% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.50 | +1.88% |
Figures last refreshed Aug 18, 2026.